belinostat + dexamethasone

Belinostat + dexamethasone is a combination therapy comprising **belinostat**, a small molecule histone deacetylase (HDAC) inhibitor, and **dexamethasone**, a synthetic glucocorticoid corticosteroid. Belinostat acts as an epigenetic modulator, increasing acetylation of histone proteins and inducing apoptosis and cell cycle arrest in malignant cells. Dexamethasone modulates inflammation and immune responses and is cytotoxic to certain lymphoid malignancy cells. This combination (sometimes called "BelDex") has demonstrated modest activity in patients with hematologic malignancies such as multiple myeloma and was studied in peripheral T-cell lymphoma (PTCL). The rationale is that their distinct but potentially synergistic mechanisms (epigenetic modulation by belinostat and anti-inflammatory/lympholytic effect by dexamethasone) may enhance antitumor efficacy while limiting overlapping toxicities[2][1].